Breaking News

Cellino’s iPSC Manufacturing Technology Receives FDA AMT Designation

Cellino will accelerate the development of scalable, personalized regenerative medicines.

By: Rachel Klemovitch

Assistant Editor

Cellino announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA’s Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER).  This designation highlights the potential of Cellino’s automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. Autologous iPSC manufacturing has been one of the most complex cha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters